Akshanth R Polepally

13PUBLICATIONS
32CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 14, 2026
Population Pharmacokinetics and Exposure-Response Analyses to Support Cofetuzumab Pelidotin (ABBV-647) Dose Optimization in Non-Small Cell Lung Cancer Patients.

|May 10, 2026
Semi-Mechanistic PK/PD Modeling of Platelets and Spleen Volume With Navitoclax in Combination With Ruxolitinib in Patients With Myelofibrosis.

|Mar 27, 2025
Pharmacokinetics and Safety of Navitoclax in Hepatic Impairment.

Maulik Patel, Jalaja Potluri, Thomas Marbury

|Nov 30, 2023
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study.

Carla Biesdorf, Xiaowen Guan, Satya R Siddani

|Aug 27, 2022
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.

Anita D'Souza, Nina Shah, Cesar Rodriguez

|Apr 06, 2021
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors.

George D Demetri, Jason J Luke, Antoine Hollebecque

Pageof 3

Frequent Collaborators

3 joint publications

Insa Winzenborg

3 joint publications

Ahmed Nader

3 joint publications

Rajeev M Menon

3 joint publications

Carla Biesdorf